StockNYSEBMY

Bristol Myers Squibb

61,50 $

-0.05 (-0.08%)heute

Valuation & earnings

P/E ratio: 13.49
Forward P/E: 9.37
EPS (ttm): $4.56
Forward EPS: $6.56
Price/book: 5.63
PEG ratio: 17.03
Dividend yield: 4.12%
Payout ratio: 55.29%

Financials (ttm)

Revenue (ttm): 49.2B
Revenue growth: 5.7%
Profit margin: 18.87%
Return on equity: 46.6%
Total cash: 11.1B
Total debt: 45.1B

Earnings (EPS)

Quarter	Estimate	Actual	Surprise
Sep 30, 2025	1.52	1.63	+7.55%
Dec 31, 2025	1.2	1.26	+4.57%
Mar 31, 2026	1.42	1.58	+11.18%
Jun 30, 2026	1.6	2.04	+27.74%

Next earnings date: Oct 29, 2026

Analyst view

Consensus ratingBuy28 analysts

Strong buy 3Buy 7Hold 17Sell 1

12-month price targetsImplied upside: +8.47%

66.71

LowCurrent priceHigh

Dividends

Dividend yield: 4.12%
Dividend (annual): $2.52
Ex-dividend date: Oct 2, 2026

Recent payments

Jul 2, 2026 · $0.63Apr 2, 2026 · $0.63Jan 2, 2026 · $0.63Oct 3, 2025 · $0.62Jul 3, 2025 · $0.62

Key stats

Previous close: $61.55
Day range: 60.6 – 61.59
52-week range: 42.52 – 68.64
Volume: 14.9M
Avg. volume: 11.1M
Market cap: 125.6B
Beta: 0.23
52-week change: 39.39%
Currency: USD

Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell l(English)

Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 32,500
Headquarters: Princeton, United States

Visit website

Market data provided by Yahoo Finance, may be delayed. For informational purposes only — not investment advice.